

CEO name: Ofer Sharon, MD

CATEGORY: Biotech/Pharma SESSIONS • Liquid biopsy & Diagnostics: Getting closer to transforming early detection and disease management

- o Executive Summary / Investment Rational OncoHost's plasma proteomics PROphet® platform guides first-line immunotherapy decisions, which up to 80% of metastatic lung cancer patients receive. Current biomarkers provide little treatment planning guidance, leading to low immunotherapy response rates. PROphet® NSCLC, launched in the US in February 2023, addresses this unmet need. \$40M raised to date. Led by industry experts and supported by a large-scale clinical trial.

- o Core Technology OncoHost's PROphet® NSCLC test uses machine learning (ML) and plasma proteomic pattern analysis to guide first-line immunotherapy decisions by predicting patient clinical benefit. Offering personalized treatment guidance, PROphet® significantly improves overall survival rates. By applying ML to liquid assays in proteomics, OncoHost has created a new generation of tests with clear clinical utility for physicians treating patients with advanced disease.

- o Product Profile/Pipeline OncoHost's expanding its pipeline to new indications and treatment modalities, while planning to inlicense and develop additional capabilities, including single cell analysis, post translational modifications and cell-free DNA, covering the most advanced precision medicine technologies. An immune-related adverse events predictor is in the pipeline. Recent collaboration: Hengenix Biotech, using PROphet® as an exploratory biomarker in a Phase III clinical trial.

- o Business Strategy OncoHost launched PROphet® NSCLC as a laboratory-developed test (LDT) in 2023. The company will aim for an FDA-approved companion diagnostic label for the product for specific drug combinations following a PMA process. OncoHost is pursuing CMS reimbursement, offers a patient assistance program, and is billing commercial insurance plans using a generic CPT code while seeking a dedicated PROphet® code.

- o What's Next? Continuous improvement of computation engine and biological validation, expanding to new indications. Ongoing patient recruitment for multicenter clinical trial. Expanding team with qualified technical, business development, and management personnel. Raising a C1 investment round to achieve CMS reimbursement, expand the platform for more tests, advance clinical validation for new indications, grow US sales and clinical support team, and develop pipeline.